Contraception in obese women

  • Authors: Andreeva E.1, Sokolova D.2, Grigoryan O.3
  • Affiliations:
    1. Endocrinology Research Centre, Moscow, Russia Moscow State University of Medicine and Dentistry, Moscow, Russia
    2. Endocrinology Research Centre, Moscow, Russia
    3. Endocrinology Research Centre, Moscow, Russia I.M. Sechenov’s First Moscow State Medical University, Moscow, Russia
  • Issue: Vol 13, No 3 (2016)
  • Pages: 65-69
  • Section: Lecture
  • URL: https://omet-endojournals.ru/omet/article/view/8207
  • DOI: https://doi.org/10.14341/omet2016365-69
  • Cite item

Abstract


At present, the prevalence of overweight people in the world is more than 1.7 billion; 312 million people are obese. The 25% of them consist of reproductive age women. In the modern world contraception is not only the way to prevent unscheduled pregnancy but also the opportunity to treat endocrine and gynecological diseases. While choosing the method of contraception, it is important to realize it’s pharmacological effect on carbohydrate and lipid metabolism, hemocoagulation/fibrinolysis system, cardiovascular and other systems of body that are involved in cascade of pathological processes. Selection of contraception for overweight/obese patients needs an individualized approaches with evaluation of efficiency/risk for every specific method of fertility correction.

About the authors

Elena Andreeva

Endocrinology Research Centre, Moscow, Russia
Moscow State University of Medicine and Dentistry, Moscow, Russia

Author for correspondence.
Email: endogin@mail.ru
SPIN-code: 1239-2937

Russian Federation д.м.н.

Dar’y Sokolova

Endocrinology Research Centre, Moscow, Russia

Email: endogin@mail.ru

Russian Federation resident

Ol'ga Grigoryan

Endocrinology Research Centre, Moscow, Russia
I.M. Sechenov’s First Moscow State Medical University, Moscow, Russia

Email: iceberg1995@mail.ru
SPIN-code: 3060-8242

Russian Federation MD, ScD

References

  1. Ершова Е.В., Трошина Е.А., Федорова О.С., Бутрова С.А.. Морбидное ожирение – возможности консервативной терапии // Ожирение и метаболизм. – 2010. – Т. 7. – №4 – C. 40-43. [Ershova EV, Troshina EA, Fedorova OS, Butrova SA. Morbidnoe ozhirenie – vozmozhnostikonservativnoy terapii. Obesity and metabolism. 2010;7(4):40-43.] doi: 10.14341/2071-8713-5087
  2. Прилепская В.Н., Новикова Е.П. Дроспиренон-содержащие контрацептивные средства–возможности расширяются. // Фарматека. – 2012. – №. 12. – С. 49-52. [Prilepskaya VN., Novikova E.P. Drospirenon-soderzhashchie kontratseptivnye sredstva–vozmozhnosti rasshiryayutsya. Farmateka. 2012;(12):49-52. (In Russ.)]
  3. Андреева Е.Н., Шереметьева Е.В., Дедов И.И. Синдром поликистозных яичников: этиология, патогенез, диагностика и лечение. Научно-практическое руководство. Москва.2014. [Andreeva EN, Sheremet’eva EV, Dedov II. Sindrom polikistoznykh yaichnikov: etiologiya, patogenez, diagnostika i lechenie. Nauchno-prakticheskoe rukovodstvo. Moscow; 2014. (In Russ.)]
  4. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol. 2012;24(4):235-40. doi: 10.1097/GCO.0b013e328355871d
  5. Андреева Е.Н., Григорян О.Р. Контрацепция при эндокринопатиях. Доказательная база. Научно-практическое руководство. Москва, 2016 [Andreeva EN, Grigoryan OR. Kontratseptsiya pri endokrinopatiyakh. Dokazatel’naya baza. Nauchno-prakticheskoe rukovodstvo. Moscow; 2016 (In Russ.)]
  6. Макаров И.О., Боровкова Е.И. Контрацепция у пациенток с ожирением //Акушерство, гинекология и репродукция. – 2013. – Т. 7. – №. 1. – C. 36-40. [Makarov IO, Borovkova EI. Kontratseptsiya u patsientok s ozhireniem. Akusherstvo, ginekologiya i reproduktsiya. 2013;7(1):36-40. (In Russ.)]
  7. Trussell J, Schwarz EB, Guthrie K. Obesity and oral contraceptive pill failure Contraception. 2009;79(5):334-8. doi: 10.1016/j.contraception.2008.11.017
  8. Шестакова И.Г., Хамошина М.Б., Кайгородова Л.А. Дифференцированный̆ подход к назначению левоноргестрелвыделяющей внутриматочной системы // Доктор.Ру. Гинекология. Эндокринология. – 2014. – № 8–2 (96). – С. 5–11. [Shestakova IG, Khamoshina MB, Kaĭgorodova LA. Differentsirovannyy̆ podkhod k naznacheniyu levonorgestrelvydelyayushcheĭ vnutrimatochnoĭ sistemy. Doktor.Ru. Ginekologiya. Endokrinologiya. 2014;(8–2 (96):5–11. (In Russ.)]
  9. Межевитинова Е.А., Бурлев В.А., Набиева К.Р., и др. Комплексная оценка эффективности, переносимости и безопасности комбинированного гормонального контрацептива третьего поколения // Медицинский̆ совет. – 2015. – №9. – С. 54–61. [Mezhevitinova EA, Burlev VA, Nabieva KR, et al. Kompleksnaya otsenka effektivnosti, perenosimosti i bezopasnosti kombinirovannogo gormonal’nogo kontratseptiva tret’ego pokoleniya. Meditsinskiy̆ sovet. 2015;(9):54–61. (In Russ.)]
  10. World Health Organzation. Medical eligibility criteria for contraceptive use. Fifth edition, 2015. Geneva; Switzerland: World Health Organization, 2015. Available at http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/
  11. DeLeo V, Fruzzetti F, Musacchio MC, et al. Effect of a new oral contraceptive with estradiol valerate/dien- ogest on carbohydrate metabolism. Contraception. 2013;88(3):364-8 doi: 10.1016/j.contraception.2012.09.003
  12. Edelman AB, Cherala G, Munar MY, et al. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. Contraception. 2014 Nov;90(5):550-6. doi: 10.1016/j.contraception.2014.06.033
  13. Grandi G, Piacenti I. Volpe A, Cagnacci A. Modification of body com- position and metabolism during oral contraceptives containing non-androenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol. 2014;30(9): 676–80 doi: 10.3109/09513590.2014.922947
  14. Kaunitz AM, Archer DF, Mishell DR. Jr, Foegh M. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. Am J Obstet Gynecol. 2015;212(3):318.e1-8. doi: 10.1016/j.ajog.2014.09.014
  15. Lopez LM, Grimes DA, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2013;30(4):CD008452. doi: 10.1002/14651858.cd008452.pub3
  16. Mayeda ER, Torgal AH, Westhoff CL. Weight and body composition changes during oral contraceptive use in obese and normal weight women. J Womens Health (Larchmt). 201423(1):38-43. doi: 10.1089/jwh.2012.4241
  17. McNicholas C, Zhao Q, Secura G, et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol. 2013 Mar;121(3):585-92. doi: 10.1097/AOG.0b013e31828317cc
  18. Shaw K. A., Edelman A. B. Obesity and oral contraceptives: a clinician’s guide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):55-65. doi: 10.1016/j.beem.2012.09.001
  19. Endrikat J, Blode H, Gerlinger C, et al. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microgethinylestradiol plus 100 microg levonorgestrel. The European Journal of Contraception & Reproductive Health Care 2002; 7:79–90. doi: 10.1080/ejc.7.2.79.90
  20. Sitruk-Ware R, Plu-Bureau G, Menard J, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. JCEM. 2007;92:2074–2079. doi: 10.1210/jc.2007-0026
  21. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Original research article. Contraception. 2016;94(4):328-339. doi: 10.1016/j.contraception.2016.06.010

Statistics

Views

Abstract - 1578

PDF (Russian) - 1624

Cited-By


Dimensions


Copyright (c) 2016 Андреева Е.Н., Соколова Д.А., Григорян О.Р.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies